Mark Ragosa - Jan 3, 2024 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
Jan 3, 2024
Transactions value $
-$134,040
Form type
4
Date filed
1/4/2024, 04:30 PM
Previous filing
Sep 6, 2023
Next filing
Apr 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise $106K +12K +76.77% $8.83 27.6K Jan 3, 2024 Direct F1
transaction KNSA Class A Common Share Sale -$240K -12K -43.43% $20.00 15.6K Jan 3, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Options Exercise $0 -12K -100% $0.00* 0 Jan 3, 2024 Class A Common Share 12K $8.83 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 22, 2023.
F2 This option is fully vested and exercisable.